Coversyl Plus Dosage/Direction for Use

Posology: 5 mg/1.25 mg Tablet: One Coversyl Plus 5mg/1.25mg film-coated tablet per day as a single dose, preferably to be taken in the morning, and before a meal.
When possible individual dose titration with the components is recommended. Coversyl Plus 5mg/1.25mg film-coated tablet should be used when blood pressure is not adequately controlled on Coversyl Plus 2.5mg/0.625mg film-coated tablet (where available). When clinically appropriate, direct change from monotherapy to Coversyl Plus 5mg/1.25mg film-coated tablet may be considered.
Special populations: Elderly (see Precautions): Treatment should be initiated after considering blood pressure response and renal function.
Renal impairment (see Precautions): In severe renal impairment (creatinine clearance below 30 ml/min), treatment is contraindicated.
In patients with moderate renal impairment (creatinine clearance 30-60 ml/min), it is recommended to start treatment with the adequate dosage of the free combination.
In patients with creatinine clearance greater than or equal to 60 ml/min, no dose modification is required. Usual medical follow-up will include frequent monitoring of creatinine and potassium.
Hepatic impairment (see Contraindications, Warnings, Precautions and Pharmacology: Pharmacokinetics under Actions): In severe hepatic impairment, treatment is contraindicated.
In patients with moderate hepatic impairment, no dose modification is required.
Paediatric population: The safety and efficacy of perindopril arginine/indapamide in the paediatric population have not yet been established. No data are available.
Coversyl Plus 5mg/1.25mg should not be used in children and adolescents.
10 mg/2.5 mg Tablet: One Coversyl Plus 10mg/2.5mg tablet per day as a single dose, preferably to be taken in the morning, and before a meal.
Special populations: Elderly (see Precautions): In elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated if renal function is normal and after considering blood pressure response.
Renal impairment (see Precautions): In severe and moderate renal impairment (creatinine clearance below 60 ml/min), treatment is contraindicated.
Usual medical follow-up will include frequent monitoring of creatinine and potassium.
Hepatic impairment (see Contraindications, Warnings, Precautions and Pharmacology: Pharmacokinetics under Actions): In severe hepatic impairment, treatment is contraindicated.
In patients with moderate hepatic impairment, no dose modification is required.
Paediatric population: The safety and efficacy of Coversyl Plus 10mg/2.5mg in children and adolescents have not yet been established. No data are available. Coversyl Plus 10mg/2.5mg should not be used in children and adolescents.
Method of administration: Oral use.